Inhibikase Therapeutics, Inc. · NASDAQ:IKT
Perceptive Advisors LLC reported a 8.90% stake in Inhibikase Therapeutics, Inc. (Schedule 13G/A)
Event Mar 31, 2026 · Filed May 15, 2026
Perceptive Advisors LLC reported a 8.90% stake in Inhibikase Therapeutics, Inc., 12,635,875 shares, as a passive investor on Mar 31, 2026. Filed May 15, 2026 (Schedule 13G/A).
- Stake
- 8.90%
- Shares
- 12,635,875
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 3 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Perceptive Advisors LLC | 8.90% | 12,635,875 |
| Joseph Edelman | 8.90% | 12,635,875 |
| Perceptive Life Sciences Master Fund, Ltd. | 8.90% | 12,635,875 |
Source
Related
- Inhibikase Therapeutics, Inc.
- Perceptive Advisors LLC
- Inhibikase Therapeutics, Inc. shareholders
- Schedule 13G/A · Perceptive Advisors LLC · Aug 14, 2026
- Schedule 13G/A · Perceptive Advisors LLC · Feb 17, 2026
- Schedule 13G/A · Nantahala Capital Management, LLC · Aug 14, 2026
- Schedule 13G/A · Sands Capital Life Sciences Pulse Fund II, L.P. · Aug 13, 2026
- Form 4 · Berman Dennis N · Jul 31, 2026
- Form 4 · RA Capital Healthcare Fund LP · Jul 31, 2026
- Schedule 13G/A · Ra Capital Management, L.P. · Jul 31, 2026